Clinical Trials Logo

Angioplasty clinical trials

View clinical trials related to Angioplasty.

Filter by:

NCT ID: NCT02214082 Completed - Angioplasty Clinical Trials

Safety of Same Day Discharge After Elective Percutaneous Coronary Intervention

Start date: September 2014
Phase: N/A
Study type: Interventional

Study intends to determine if there is any difference in the occurrence of major adverse cardiology events in patients discharged on the same day as their elective cardiac angioplasty or discharged one day after their angioplasty. Hypothesize that same day discharge is as safe as a day later discharge.

NCT ID: NCT01894152 Completed - Clinical trials for Coronary Artery Disease

XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study

XP China SAS
Start date: July 2013
Phase:
Study type: Observational

Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug Administration (CFDA) on August 10th, 2011. This prospective, observational, open-label, multi-center, single-arm, post-approval study is designed to evaluate the continued safety and effectiveness of the XIENCE PRIME EECSS in a cohort of real-world patients receiving the XIENCE PRIME EECSS during commercial use in real-world settings in China. This study has no primary outcome measure. All observations are of equal weight.

NCT ID: NCT01312935 Terminated - Clinical trials for Percutaneous Coronary Intervention

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Start date: April 2011
Phase: Phase 2
Study type: Interventional

The study investigates the safety and efficacy of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

NCT ID: NCT01249027 Completed - Clinical trials for Coronary Artery Disease

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

XV CHINA SAS
Start date: November 2010
Phase:
Study type: Observational

This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: - Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use - Evaluate patient compliance to dual antiplatelet therapy (DAPT)

NCT ID: NCT01245803 Recruiting - Clinical trials for Acute Coronary Syndrome

Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS

AVATAR
Start date: April 2010
Phase: Phase 4
Study type: Interventional

Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI

NCT ID: NCT01180517 Completed - Angioplasty Clinical Trials

The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations

PEPCAD-BIF
Start date: November 2010
Phase: Phase 4
Study type: Interventional

The intention of this trial is to assess the safety and efficacy of Drug Eluting Balloon (DEB) application (SeQuent Please) to the side branch in percutaneous coronary intervention (PCI) of Medina 0,0,1 coronary bifurcation lesions. Patients will be randomized to treatment with Plain Old Balloon Angioplasty (POBA)or treatment with DEB.

NCT ID: NCT01174472 Completed - Dialysis Clinical Trials

Drug Eluting Balloon Angioplasty for Dialysis Access Treatment

Start date: March 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of the study is to compare the feasibility and the effectiveness, by means of immediate and long-term results, of drug eluting balloon (DEB) versus conventional balloon angioplasty for the treatment of failing dialysis access.

NCT ID: NCT01080638 Recruiting - Clinical trials for Myocardial Infarction

Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.

Start date: October 2009
Phase: Phase 4
Study type: Interventional

Intracoronary bolus Abciximab single is non-inferior to intravenous and continuous 12- hours infusion in the size reduction of infarction on cardiac magnetic resonance in Non-ST elevation Myocardial infarction.

NCT ID: NCT00858715 Completed - Atherosclerosis Clinical Trials

Resistance to Antithrombotic Therapy

Vienna REACT
Start date: May 2008
Phase: N/A
Study type: Interventional

Clopidogrel plays a pivotal role in the antithrombotic regimen after percutaneous intervention with stent implantation. However, response to clopidogrel shows a wide interindividual variability and a high on-treatment residual ADP-inducible platelet reactivity has already been associated with an increased risk for adverse events after coronary stenting. In the present study, platelet reactivity will be determined by 6 different platelet function tests in patients on dual antiplatelet therapy after angioplasty and stenting for peripheral, coronary and carotid artery disease. One hundred patients showing high on-treatment residual ADP-inducible platelet reactivity in 2 or more tests will be randomized to receive either 75mg or 150mg of daily clopidogrel in addition to aspirin for 3 months. The aim of the present study is to investigate the effects of intensified antithrombotic therapy (150mg clopidogrel + 100mg aspirin daily) versus standard antithrombotic therapy (75mg clopidogrel + 100mg aspirin daily) in patients with decreased clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.

NCT ID: NCT00821028 Completed - Atherosclerosis Clinical Trials

Local Paclitaxel Delivery for SFA Disease

IRRITAX
Start date: January 2009
Phase: N/A
Study type: Interventional

To see if restenosis rates of superficial femoral artery atherosclerosis with percutaneous techniques can be improved using paclitaxel.